India · Delayed Price · Currency is INR Vijaya Diagnostic Centre Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw 26.6% YoY revenue growth and 43.5% EBITDA margin, driven by strong volume and network expansion. FY 2026 revenue reached INR 814 crore, with robust growth across core and new geographies, and continued investment in technology and talent.
-
Q3 FY26 saw record revenue of INR 205 crore, up 21.4% year-over-year, with strong growth in both radiology and pathology. EBITDA margin improved to 41.9%, and the wellness segment reached 15% of revenue. Expansion continues with a focus on stabilizing new hubs and investing in technology.
-
Q2 FY26 saw 10.2% YoY revenue growth and strong margins, led by radiology and new hub launches. Guidance for 15% CAGR and 38-40% EBITDA margin is maintained, with expansion focused on Bengaluru, Kolkata, and tier-two cities.
-
Q1 FY26 saw 20.4% revenue growth, strong margins, and robust volume gains, with new hubs ramping up well and Hyderabad returning to double-digit growth. Guidance for 15%+ revenue growth and 38%-39% EBITDA margin is maintained, with continued expansion and market share gains in new geographies.
Fiscal Year 2025
-
Revenue grew 12% YoY in Q4 and 24% for FY25, driven by organic test volume and network expansion. Margins dipped due to wellness mix and new hub ramp-up, but normalization is expected by end-FY26. CapEx of INR 140-150 crores planned for FY26, with 15%+ CAGR growth targeted.
-
Q3 FY25 saw 27% revenue growth (20% organic), with strong volume gains and robust margins. Expansion continues with 14 new hubs planned, a stable net cash position, and a 15% CAGR target, though near-term margins may dip slightly as new centers ramp up.
-
Q2 FY25 saw 32% revenue growth (23% organic), driven by strong volume and rapid expansion, with EBITDA margin at 41.5% and PAT margin at 23%. Expansion continues in new geographies, funded by robust internal accruals, while maintaining industry-leading gross margins and a debt-free balance sheet.
-
Q1FY25 saw 29% YoY revenue growth, strong margins (39% EBITDA), and robust expansion with nine new hubs planned. B2C and wellness segments performed well, and all but one new hub are EBITDA positive. Expansion is funded internally, with margins expected to remain stable.